Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1

Whitaker, Jennifer A.; Rouphael, Nadine; Edupuganti, Srilatha; Lai, Lilin; Mulligan, Mark J.

doi:10.1016/s1473-3099(12)70243-8

Cited by 79 publications

(58 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prevention research efforts in the setting of HIV infection should include smoking cessation [51, 52]; validation and optimization of computed tomography screening for lung cancer [53, 54], ultrasonography screening for HCC [55], and anal dysplasia screening for anal cancer [56]; optimization of HBV vaccination for HCC [57, 58] and HPV vaccination for HPV-related cancers [59–63]; and optimization of HCV [64, 65], HBV [57, 66], and alcohol abuse/dependence treatment [67, 68] for HCC. Prostate specific antigen screening for prostate cancer is controversial [69].…”

Section: Discussionmentioning

confidence: 99%

Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era

Park

Tate

Sigel

et al. 2016

Aids

View full text Add to dashboard Cite

Objective Utilizing the Veterans Aging Cohort Study, the largest HIV cohort in North America, we conducted one of the few comprehensive comparisons of cancer incidence time trends in HIV-infected (HIV+) versus uninfected persons during the antiretroviral therapy (ART) era. Design Prospective cohort study. Methods We followed 44,787 HIV+ and 96,852 demographically-matched uninfected persons during 1997–2012. We calculated age-, sex-, and race/ethnicity-standardized incidence rates (IR) and incidence rate ratios (IRR, HIV+ versus uninfected) over four calendar periods with IR and IRR period trend p-values for cancer groupings and specific cancer types. Results We observed 3,714 incident cancer diagnoses in HIV+ and 5,760 in uninfected persons. The HIV+ all cancer crude IR increased between 1997–2000 and 2009–2012 (p-trend=0.0019). However, after standardization, we observed highly significant HIV+ IR declines for all cancer (25% decline; p-trend<0.0001), AIDS-defining cancers (ADC; 55% decline; p-trend<0.0001), non-AIDS-defining cancers (NADC; 15% decline; p-trend=0.0003), and non-virus-related NADC (20% decline; p-trend<0.0001); significant IRR declines for all cancer (from 2.0 to 1.6; p-trend<0.0001), ADC (from 19 to 5.5; p-trend<0.0001), and non-virus-related NADC (from 1.4 to 1.2; p-trend=0.049); and borderline significant IRR declines for NADC (from 1.6 to 1.4; p-trend=0.078) and virus-related NADC (from 4.9 to 3.5; p-trend=0.071). Conclusion Improved HIV care resulting in improved immune function most likely contributed to the HIV+ IR and the IRR declines. Further promotion of early and sustained ART, improved ART regimens, reduction of traditional cancer risk factor (e.g., smoking) prevalence, and evidence-based screening could contribute to future cancer incidence declines among HIV+ persons.

show abstract

Section: Discussionmentioning

confidence: 99%

Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era

Park

Tate

Sigel

et al. 2016

Aids

View full text Add to dashboard Cite

show abstract

“…[48][49][50] Recommendations 1. All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by two or three doses of hepatitis B vaccines 51 .…”

Section: Antiviral Resistancementioning

confidence: 99%

Management of Chronic Hepatitis B in Childhood: A Comprehensive Guideline

Rukunuzzaman

Karim

Nurullah

et al. 2017

Bangladesh J Child Health

View full text Add to dashboard Cite

show abstract

“…1 Hepatitis B replication cycle HBV nor has been previously exposed, and vaccination is recommended. Currently four shots using double-doses are generally preferred for HIV persons [58,63,64].…”

Section: Hbsag+ Highmentioning

confidence: 99%

Emerging Challenges in Managing Hepatitis B in HIV Patients

et al. 2015

View full text Add to dashboard Cite

Roughly 10 % of HIV-positive individuals worldwide have concomitant chronic hepatitis B virus (HBV) infection, with large differences between geographical regions and/or risk groups. Hepatitis B is a preventable infection with vaccines. However, it cannot be eradicated once acquired, resembling HIV and in contrast with HCV. In developed countries, hepatitis B exhibits particular features in the HIV population. First, HBV infection is less frequently misdiagnosed than in the general population. Second, nucleos(t)ide analogs active against HBV are widely used as part of antiretroviral combinations and are taken by most HIV patients. Lastly, as the HIV population ages given the success of antiretroviral therapy, non-AIDS co-morbidities are becoming a major cause of disease, for which specific drugs are required, increasing the risk of interactions and hepatotoxicity. Furthermore, concern on HBV reactivation is rising as immunosuppressive drug therapies are increasingly been used for cancers and other non-malignant conditions. In this scenario, new challenges are emerging in the management of hepatitis B in HIV-positive individuals. Among them, major interest is focused on failures to suppress HBV replication, HBV breakthroughs and reactivations, the meaning of isolated anti-HBc, screening for liver cancer, and the complexity arising when hepatitis viruses C and/or D are additionally present. This review will focus on these challenges and the major advances in HBV coinfection in HIV.

show abstract

Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1

Cited by 79 publications

References 97 publications

Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era

Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era

Management of Chronic Hepatitis B in Childhood: A Comprehensive Guideline

Emerging Challenges in Managing Hepatitis B in HIV Patients

Contact Info

Product

Resources

About